EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Evidence of decreased plasma substance p levels in human essential hypertension influence of prazosin treatment


Biomedica Biochimica Acta 42(7-8): 1019-1026
Evidence of decreased plasma substance p levels in human essential hypertension influence of prazosin treatment
Patients with essential hypertension (n = 45) had significantly lower substance P plasma levels (13.6 .+-. 2.30 pg/ml) in comparison with a group of 24 normotensive subjects (45.4 .+-. 7.18 pg/ml) analyzed by radioimmunoassay. Prazosin treatment for 2 wk with 4.5 mg/day enhanced the substance P plasma level depending on its antihypertensive effect. Norepinephrine concentration in plasma was also elevated by prazosin. Dipeptidylpeptidase IV, dopamine-.beta.-hydroxylase and plasma renin activity were not changed significantly. Evidently, substance P participates in pathophysiological processes of human essential hypertension.


Accession: 005411339



Related references

Evidence of decreased plasma substance P levels in human essential hypertension and influence of prazosin treatment. Biomedica Biochimica Acta 42(7-8): 1019-1025, 1983

Open studies with prazosin in the treatment of essential hypertension. Prazosin Research Group in Japan. Medical Journal of Australia 2(2 Suppl): 38-41, 1977

Central and renal circulation renin and aldo sterone in plasma during prazosin treatment in essential hypertension. Acta Medica Scandinavica 206(6): 489-494, 1979

Plasma levels of digitalis-like substance in Nigerians with essential hypertension. African Journal of Medicine and Medical Sciences 17(4): 231-235, 1988

Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. Journal of Hypertension 23(9): 1725-1729, 2005

The effect of long-term prazosin treatment on plasma follitropin (FSH), lutropin (LH), prolactin, estradiol and testosterone concentration in male patients with essential hypertension. Polskie Archiwum Medycyny Wewnetrznej 89(2): 125-135, 1993

Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. American Journal Of Hypertension. 10(12 Part 1): 1326-1334,., 1997

Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. American Journal of Hypertension 10(12 Pt 1): 1326-1334, 1998

Decreased renal plasma flow during propranolol treatment in essential hypertension. Acta Medica Scandinavica 205(1-2): 91-96, 1979

Verapamil and prazosin in essential hypertension: evidence of a synergistic combination?. Journal of Cardiovascular Pharmacology 10 Suppl 10: S108-S110, 1987